Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18494021 | 0.80 | POLB (0.31) | POLB | |
| SCHEMBL605889 | 0.76 | GAA (0.48) | GAAPOLBKDM4EALDH1A1HTT | |
| SCHEMBL22752563 | 0.73 | GAA (0.32) | GAA | |
| SCHEMBL154812 | 0.72 | POLB (0.46) | GAAPOLBKDM4EALDH1A1 | |
| SCHEMBL7122548 | 0.71 | NPSR1 (0.31) | GAAALDH1A1 | |
| SCHEMBL1760354 | 0.69 | — | — | |
| SCHEMBL4553950 | 0.69 | — | — | |
| SCHEMBL138983 | 0.69 | — | — | |
| SCHEMBL6635180 | 0.69 | ALDH1A1 (0.39) | GAAALDH1A1 | |
| SCHEMBL6967172 | 0.67 | APLNR (0.49) | GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10300109-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | AILERON THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-11-10 | — | — | US | disclosed |
| US-4906661-A | Esters of aryloxypropanolamine derivatives | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4804677-A | CARDIOTONIC AGENTS; GLAUCOMA; SIDE-EFFECT REDUCTION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-14 | — | — | US | disclosed |
| US-4692446-A | ADRENERGIC BLOCKING AGENTS | E. I. DU PONT DE NEMOURS & CO., INC. (US) | 1987-09-08 | — | — | US | disclosed |
| US-4623652-A | ADRENERGIC BLOCKING AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0093155-B1 | ESTERS OF ARYLOXYPROPANOLAMINE DERIVATIVES AND USE AS BETA-ADRENERGIC BLOCKING AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0093155-A4 | ESTERS OF ARYLOXYPROPANOLAMINE DERIVATIVES AND USE AS BETA-ADRENERGIC BLOCKING AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1984-04-24 | — | — | EP | disclosed |
| EP-0093155-A1 | ESTERS OF ARYLOXYPROPANOLAMINE DERIVATIVES AND USE AS BETA-ADRENERGIC BLOCKING AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-11-09 | — | — | EP | disclosed |
| WO-1983001772-A1 | ESTERS OF ARYLOXYPROPANOLAMINE DERIVATIVES AND USE AS 'beta'-ADRENERGIC BLOCKING AGENTS | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, CTNNB1, WNT1 | GAA 4399/4885POLB 2996/4885KDM4E 1936/4885 |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | HIF1A, HIF1AN, EGLN3 | GAA 2039/4885POLB 3845/4885KDM4E 2279/4885 |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | GAA 2540/4885POLB 3290/4885KDM4E 4317/4885 |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | KIT, NISCH, FLT3 | GAA 2834/4885POLB 2054/4885KDM4E 2842/4885 |
| US-10300109-B2 | Peptidomimetic macrocycles | TCF4, CTNNB1, WNT1 | GAA 4399/4885POLB 2996/4885KDM4E 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.